Summary

Abiraterone acetate as therapy for chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) improved overall survival (OS) compared with placebo in the final OS analysis of the phase 3 COU-AA-302 clinical trial. This article discusses data from more than 4 years of follow-up from the international, randomized, double-blind, placebo-controlled COU-AA-302. Abiraterone is an orally available inhibitor of the CYP17 enzyme complex, a key regulator of androgen synthesis.